Durham
-
Precision Bio Offloads Lead Cell Therapy Program in Pivot to In Vivo Gene Editing
Imugene gains global rights to Precision BioSciences’ most advanced program, an allogeneic cell therapy for advanced cases of blood cancer. Precision will now focus on in vivo gene editing therapies, some of which is partnered with Novartis and Eli Lilly.
-
Moderna Signs On a New Partner in Quest for In Vivo mRNA Gene Editing
Moderna is partnering with Life Edit, a subsidiary of ElevateBio that offers a suite of gene-editing technologies. The deal brings together the capabilities of both companies, which aim to develop in vivo gene-editing therapies.Mod
-
Trayt Health Seeks to Increase Access to Diagnoses and Treatments
CEO Malekeh Amini explains how Trayt Health can bridge the gap for patients seeking neurological care.
-
Novartis picks Precision Bio to bring in vivo gene editing meds to blood disorders
Novartis is paying Precision Bio $75 million up front to begin a partnership aiming to develop in vivo gene-editing therapies for serious genetic blood disorders, such as sickle cell disease. One of the goals of the alliance is to make genetic medicines more globally accessible.
-
Becton Dickinson buys into pharmacy automation with $1.5B Parata acquisition
Becton Dickinson is getting into pharmacies with a more than $1.5 billion acquisition of Parata Systems, maker of robotics technologies that automate pharmacy tasks. The deal comes two months after BD completed the spinoff of its diabetes business as a separate, publicly traded company.
-
Covid-19 vaccines & therapies helped push medicines spending to $407B in 2021
While Covid-19 has had a significant impact on drug spending, IQVIA projects that its effect will moderate in coming years. IQVIA’s new report on U.S. medicines spending projects that immunology, oncology, and neurology will continue to drive the growth in drug spending.
-
IQVIA report: Drug R&D reaches new highs, and not just for Covid-19 products
The biopharmaceutical industry continues to be a hotbed of activity, with more than 6,000 products in active development and a growing share of that innovation coming from new geographic regions. The findings are from a new industry report from IQVIA.
-
Biotech startup using AI to take guesswork out of cancer drug selection raises $70M
Xilis is developing technology that creates a living model of a patient’s tumor, then applies artificial intelligence to determine the best drug or drug combinations to treat the cancer. Clinical trials are planned to test this precision medicine approach and the biotech startup has raised $70 million to fund its research.
-
Improving Communication Between Patients and Providers
Sarah Shillington, Chief Customer Officer notes how Artera’s omnichannel platform works.
-
CRO Parexel changes private equity hands again, this time for $8.5B
Four years after a private equity acquisition took Parexel private, the contract research organization is being acquired by two private equity firms for $8.5 billion. It’s the latest in a series of acquisitions to hit the CRO sector this year.
-
IQVIA adds to growing lab biz with $198M deal for Myriad contract services unit
IQVIA is paying nearly $200 million to purchase a Myriad Genetics subsidiary that provides pharmaceutical contract services, a deal that will put the new acquisition in the company’s Q2 Solutions unit. The deal follows IQVIA’s April announcement that it had secured full ownership of Q2, which had been a joint venture with Quest Diagnostics.
-
IQVIA pays Quest Diagnostics $760M to get full control of central lab joint venture
IQVIA has acquired Quest Diagnostics’ minority stake in Q2 Solutions, a central laboratory services joint venture the two companies formed in 2015. But Quest will remain a preferred provider of lab testing services under an agreement with Q2.
-
BioPharma, Hospitals, Pharma, SYN
Humacyte sets out to bring regenerative medicine to Wall Street, then the world
Humacyte is going public via a SPAC merger that infuses it with $255 million for its regenerative medicine pipeline. The biotech’s technology produces universally implantable tissue that functions like human blood vessels.
-
Chimerix starts Phase II/III trial of heparin-derived blood cancer drug in Covid-19
The development of the drug, DSTAT, is based on preclinical research indicating it can inhibit the inflammatory cytokines involved in the cytokine storms that cause much of the morbidity and mortality in Covid-19, as well as addressing the coagulation issues resulting in young patients having strokes.
-
Parexel, Datavant partner on using real-world data in clinical trials
Parexel, one of the largest CROs in the world, said the partnership would involve connecting real-world data across the clinical trials it conducts.